These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 33187531)
1. Correction to: Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A Virol J; 2020 Nov; 17(1):175. PubMed ID: 33187531 [TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977 [TBL] [Abstract][Full Text] [Related]
3. Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells. Raghunath S; Pudupakam RS; Allen A; Biswas M; Sriranganathan N J Biotechnol; 2017 Oct; 260():91-97. PubMed ID: 28935568 [TBL] [Abstract][Full Text] [Related]
4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
5. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771 [TBL] [Abstract][Full Text] [Related]
6. Correction to: Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells. Zhang F; Cui J; Liu X; Lv B; Liu X; Xie Z; Yu B Stem Cell Res Ther; 2020 Jul; 11(1):331. PubMed ID: 32736661 [TBL] [Abstract][Full Text] [Related]
7. Correction to: MSX2 suppression through inhibition of TGFβ signaling enhances hematopoietic differentiation of human embryonic stem cells. Wang H; Wang M; Wang Y; Wen Y; Chen X; Wu D; Su P; Zhou W; Shi L; Zhou J Stem Cell Res Ther; 2020 Jun; 11(1):242. PubMed ID: 32552746 [TBL] [Abstract][Full Text] [Related]
8. Correction to: Extracellular vesicles from human mesenchymal stem cells expedite chondrogenesis in 3D human degenerative disc cell cultures. Hingert D; Ekström K; Aldridge J; Crescitelli R; Brisby H Stem Cell Res Ther; 2020 Oct; 11(1):443. PubMed ID: 33066809 [TBL] [Abstract][Full Text] [Related]
9. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956 [TBL] [Abstract][Full Text] [Related]
10. Letter to the Editor on "Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL". Liu M Stem Cell Res Ther; 2017 Jun; 8(1):130. PubMed ID: 28583169 [No Abstract] [Full Text] [Related]
11. Correction to: Metabolic syndrome increases senescence-associated micro-RNAs in extracellular vesicles derived from swine and human mesenchymal stem/stromal cells. Li Y; Meng Y; Zhu X; Saadiq IM; Jordan KL; Eirin A; Lerman LO Cell Commun Signal; 2020 Oct; 18(1):171. PubMed ID: 33115493 [TBL] [Abstract][Full Text] [Related]
12. Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. Giallongo C; Tibullo D; Camiolo G; Parrinello NL; Romano A; Puglisi F; Barbato A; Conticello C; Lupo G; Anfuso CD; Lazzarino G; Volti GL; Palumbo GA; Di Raimono F Cell Death Dis; 2019 Oct; 10(11):820. PubMed ID: 31659155 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Schirrmacher V Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571 [TBL] [Abstract][Full Text] [Related]
14. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068 [TBL] [Abstract][Full Text] [Related]
15. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related]
16. Author Correction: Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma. Chen J; Ji T; Wu D; Jiang S; Zhao J; Lin H; Cai X Cell Death Dis; 2019 Jun; 10(7):488. PubMed ID: 31221997 [TBL] [Abstract][Full Text] [Related]
17. Correction to: Bone mesenchymal stem cell-derived exosomal microRNA-29b-3p prevents hypoxic-ischemic injury in rat brain by activating the PTEN-mediated Akt signaling pathway. Hou K; Li G; Zhao J; Xu B; Zhang Y; Yu J; Xu K J Neuroinflammation; 2020 Jul; 17(1):203. PubMed ID: 32635932 [TBL] [Abstract][Full Text] [Related]
18. Correction to: LncRNA-NEAT1 from the competing endogenous RNA network promotes cardioprotective efficacy of mesenchymal stem cell-derived exosomes induced by macrophage migration inhibitory factor via the miR-142-3p/FOXO1 signaling pathway. Chen H; Xia W; Hou M Stem Cell Res Ther; 2020 Sep; 11(1):376. PubMed ID: 32878634 [TBL] [Abstract][Full Text] [Related]
19. Author Correction: A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV. Shirvani E; Paldurai A; Manoharan VK; Varghese BP; Samal SK Sci Rep; 2020 Jan; 10(1):762. PubMed ID: 31937880 [TBL] [Abstract][Full Text] [Related]